首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >The influence of cationic lipid type on in-vitro release kinetic profiles of antisense oligonucleotide from cationic nanoemulsions.
【24h】

The influence of cationic lipid type on in-vitro release kinetic profiles of antisense oligonucleotide from cationic nanoemulsions.

机译:阳离子脂质类型对阳离子纳米乳液反义寡核苷酸体外释放动力学的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Novel formulations of cationic nanoemulsions based on three different lipids were developed to strengthen the attraction of the polyanionic oligonucleotide (ODN) macromolecules to the cationic moieties on the oil nanodroplets. These formulations were developed to prolong the release of the ODN from the nanoemulsion under appropriate physiological dilutions as encountered in the eye following topical application. Increasing the concentration of the new cationic lipid exhibiting two cationic amine groups (AOA) in the emulsion from 0.05% to 0.4% did not alter markedly the particle size or zeta potential value of the blank cationic nanoemulsion. The extent of ODN association did not vary significantly when the initial concentration of ODN remained constant at 10 microM irrespective of the cationic lipid nature. However, the zeta potential value dropped consistently with the low concentrations of 0.05% and 0.1% of AOA in the emulsions suggesting that an electrostatic attraction occurred between the cationiclipids and the polyanionic ODN molecules at the o/w interface. Only the nanoemulsion prepared with N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium salts (DOTAP) remained physically stable over time. DOTAP cationic lipid nanoemulsion was the most efficient formulation capable of retaining the ODN despite the high dilution of 1:100 with simulated tear solution (STS). Less than 10% of the ODN was exchanged in contrast to 40-50% with the other cationic nanoemulsions. The in-vitro release kinetic behavior of ODN exchange with physiological anions present in the STS appears to be complex and difficult to characterize using mathematical fitting model equations. Further pharmacokinetic studies are needed to verify our kinetic assumptions and confirm the in-vitro ODN release profile from DOTAP cationic nanoemulsions.
机译:开发了基于三种不同脂质的新型阳离子纳米乳剂,以增强聚阴离子寡核苷酸(ODN)大分子对油纳米滴上阳离子部分的吸引力。这些制剂被开发为在局部施用后在眼睛中遇到的适当生理稀释下延长ODN从纳米乳剂的释放。将乳状液中表现出两个阳离子胺基(AOA)的新阳离子脂质的浓度从0.05%增加到0.4%不会显着改变空白阳离子纳米乳剂的粒径或Zeta电位值。当ODN的初始浓度保持恒定在10 microM时,无论阳离子脂质的性质如何,ODN缔合的程度都不会显着变化。然而,在乳液中0.05%和0.1%的低浓度AOA时,ζ电势值始终下降,这表明在o / w界面的阳离子脂质和聚阴离子ODN分子之间发生了静电吸引。仅用N- [1-(2,3-二油酰氧基)丙基] -N,N,N-三甲基铵盐(DOTAP)制备的纳米乳液随时间推移保持物理稳定。尽管用模拟泪液(STS)以1:100的高比例稀释,但DOTAP阳离子脂质纳米乳液是能够保留ODN的最有效配方。与其他阳离子纳米乳液的40-50%相比,只有不到10%的ODN被交换。与STS中存在的生理阴离子进行ODN交换的体外释放动力学行为似乎很复杂,并且难以使用数学拟合模型方程式进行表征。需要进一步的药代动力学研究,以验证我们的动力学假设并确认DOTAP阳离子纳米乳剂的体外ODN释放曲线。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号